Chimeric enterovirus virus-like particles
AssigneeSENTINEXT THERAPEUTICS Sdn Bhd
InventorMary Jane CARDOSA
Life of this patent
Estimating the term…
Abstract
The invention provides chimeric Enterovirus virus-like particles (VLPs) for protection and/or treatment against infection by more than one Enterovirus. More specifically, the present invention provides chimeric EV-A71 virus-like particles displaying CV-A16 VP1 polypeptides and at the same time maintaining important neutralizing antibody epitopes of EV-A71 itself. More specifically, the present invention provides chimeric CV-A16 virus-like particles displaying EV-A71 VP1 polypeptides. Thus, the present invention provides a bivalent vaccine comprising the chimeric virus-like particles which elicit an immune response and/or neutralizing antibody response to both EV-A71 and CVA-16 for the treatment of Hand, Foot and Mouth Disease.
Claims21
1-36:
- (canceled)
A vaccine comprising a chimeric virus-like particle (VLP) assembled from Enterovirus EV-A71 VP0, VP2, VP4 polypeptides, Enterovirus CV-A16 VP1 polypeptides, and Enterovirus VP3 polypeptides which originate from Enterovirus EV-A71 and have up to 50 amino acids from the C-terminal portion of a VP3 polypeptide from Enterovirus CV-A16.
A vaccine comprising a chimeric VLP assembled from Enterovirus CV-A16 VP0, VP2, VP4 polypeptides, Enterovirus EV-A71 VP1 polypeptides, and Enterovirus VP3 polypeptides which originate from Enterovirus CV-A16 and have up to 50 amino acids from the C-terminal portion of a VP3 polypeptide from Enterovirus EV-A71.
A nucleic acid encoding an expression cassette comprising a nucleic acid encoding a chimeric Enterovirus P1 polypeptide, wherein the nucleic acid encoding the chimeric Enterovirus P1 polypeptide is operably linked to a nucleic acid encoding an Internal Ribosome Entry Site (IRES) and an Enterovirus 3CD protease, wherein the 3CD protease is under the translational control of the IRES.
Dependencies are inferred from the claim text.